Skip to main content

Recombinant Human IGFBP-1 Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 871-B1

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
871-B1-025

Key Product Details

Source

NS0

Accession #

Conjugate

Unconjugated

Applications

Bioactivity

Product Specifications

Source

Mouse myeloma cell line, NS0-derived human IGFBP-1 protein
Ala26-Asn259

Purity

>97%, by SDS-PAGE under reducing conditions and visualized by silver stain.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Ala26

Predicted Molecular Mass

25 kDa

SDS-PAGE

32 kDa, reducing conditions

Activity

Measured by its ability to inhibit the biological activity of IGF-I or IGF-II on MCF-7 human breast cancer cells. Karey, K.P. et al. (1988) Cancer Research 48:4083.
The ED50 for this effect is typically 0.1-0.6 µg/mL in the presence of 6 ng/mL recombinant human IGF-I.

Reviewed Applications

Read 1 review rated 5 using 871-B1 in the following applications:

Formulation, Preparation and Storage

871-B1
Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: IGFBP-1

The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and at least four additional low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-transitional modifications of IGFBP, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF.

Human IGFBP-1 cDNA encodes a 259 amino acid (aa) residue precursor protein with a putative 25 aa residue signal peptide that is processed to generate the 234 aa residue mature protein. IGFBP-1 contains an integrin receptor recognition sequence (RGD sequence) but lacks potential N-linked glycosylation sites. IGFBP-1 is expressed in liver, decidua, kidneys and is the most abundant IGFBP in amniotic fluid. Serum levels of IGFBP-1 are lowest after meals. Hepatocyte production of IGFBP-1 is regulated at the transcriptional level due to the affects of insulin and corticosteriods. IGFBP-1 binds equally well to IGF-I and IGF-II, with phosphorylated forms of IGFBP-1 exhibiting higher binding affinities.

References

  1. Jones, J.I. and D.R. Clemmons (1995) Endocrine Rev. 16:3.
  2. Kelley, K.M. et al. (1996) Int. J. Biochem. Cell Biol. 28:619.

Long Name

Insulin-like Growth Factor Binding Protein 1

Alternate Names

IGFBP1

Entrez Gene IDs

3484 (Human); 16006 (Mouse)

Gene Symbol

IGFBP1

UniProt

Additional IGFBP-1 Products

Product Documents for Recombinant Human IGFBP-1 Protein, CF

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Recombinant Human IGFBP-1 Protein, CF

For research use only

Loading...
Loading...
Loading...
Loading...